Most Read News

Quarterly revenues were 28% higher year on year at ₹4,988.4 crore from ₹3,912.7 crore in Q4 FY24.

USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.

Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

On a quarter-on-quarter basis, the company’s net profit slipped 30.90% against ₹4,649 Crore in the previous quarter.

As part of this offer, there is an offer for sale of up to 11.05 million Equity Shares.

Tejas Networks stock has witnessed a total of 38% dip in the last one year, and 11% dip in the last one month.

Net profit increased 34% YoY to ₹726.2 crore, bolstered by robust volume expansion and operating efficiency.

Out of the total April 2025 sales, 24,833 units were sold locally and 2,491 units exported, a balanced input from the domestic and overseas market.

The solar projects are located across several states in India, enhancing Inox Green's pan-India renewable energy footprint.